The sustained use of lipophilic statins for 1 year or more before a breast cancer diagnosis significantly reduced the proportion of ER/PR-negative tumors in comparison to no statin use or use for less than 1year (OR 0.63, 95% CI 0.43–0.92; p = 0.02)22. This evidence concerns the gene ESR1 and breast cancer.